Joaquin Duato

Pharmaceutical company Johnson & Johnson (NYSE:JNJ) is set to report its fourth-quarter results on Wednesday, facing one of the most important transitions in its modern history, as investors focus on whether the company can replace revenue from its former immunology powerhouse, Stelara. J&J...

Johnson & Johnson (NYSE: JNJ) announced recently a change in leadership with Alex Gorsky stepping down from his CEO role and handing the reigns to Joaquin Duato, who will take over on Jan. 3, 2022. Here are five things you might not know about Joaquin Duato, the next CEO of Johnson...

Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week. Virpax Pharmaceuticals, Inc.(NASDAQ: VRPX)...